Syngene produces SARS-CoV-2 specific, primers and probes. We provide custom oligos defined by our customers, as well as those mentioned in protocols recommended by WHO, CDC and ICMR.
Oligonucleotide therapeutics is one of the most promising ﬁelds in modern medicine to treat several diseases which are genetic or non-genetic in nature by modulating gene expression.
Oligos face immense challenges for their use as therapeutics and these challenges must be resolved before proceeding with regulatory approvals. Since a highly complex nature of oligo drugs mandates novel and sophisticated process methods, Syngene has a complete dedicated facility for oligos which satisfy the cGMP requirements.